$CYDY
CytoDyn Inc. Stock $cydy

$cydy Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000155837024012328 Filed on August 15, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.604M	$3.033M	$10.79M
YoY Change	-40.33%	8.75%	-37.04%
% of Gross Profit
Research & Development		$3.597M	$7.240M
YoY Change		266.67%	175.08%
% of Gross Profit
Depreciation & Amortization	$5.000K	$4.000K	$29.00K
YoY Change	-50.0%	-60.0%	-83.43%
% of Gross Profit
Operating Expenses	-$22.44M	$6.634M	$7.240M
YoY Change	-1272.26%	75.5%	175.08%
Operating Profit	$22.44M		-$18.06M
YoY Change	-586.49%		-55.5%
Interest Expense	-$2.016M	-$537.0K	-$6.543M
YoY Change	2.91%	-95.24%	-74.08%
% of Operating Profit	-8.99%
Other Income/Expense, Net	-$14.00K	-$1.595M	-$5.186M
YoY Change	-98.46%	71.88%	-40.32%
Pretax Income	$19.23M	-$16.79M	-$49.80M
YoY Change	-266.17%	-9.92%	-37.61%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$19.23M	-$17.16M	-$49.84M
YoY Change	-266.17%	-7.92%	-37.56%
Net Earnings / Revenue
Basic Earnings Per Share	$0.02		-$0.05
Diluted Earnings Per Share	$0.02	-$0.02	-$0.05
COMMON SHARES
Basic Shares Outstanding	1.215B		969.5M
Diluted Shares Outstanding	1.198B		969.5M

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.92M	$3.110M	$3.110M
YoY Change	1125.22%	22.39%	22.39%
Cash & Equivalents	$24.92M	$3.110M
Short-Term Investments
Other Short-Term Assets	$817.0K	$7.705M	$7.705M
YoY Change	-91.78%	-6.76%	-6.76%
Inventory		$0.00
Prepaid Expenses	$570.0K	$463.0K
Receivables
Other Receivables
Total Short-Term Assets	$27.74M	$10.82M	$10.82M
YoY Change	131.77%	0.09%	0.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$230.0K	$264.0K	$264.0K
YoY Change	-37.16%	-34.0%	-34.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$283.0K	$321.0K	$57.00K
YoY Change	-36.12%	-34.09%	-34.48%
Total Long-Term Assets	$283.0K	$321.0K	$321.0K
YoY Change	-36.12%	-34.09%	-34.09%
TOTAL ASSETS
Total Short-Term Assets	$27.74M	$10.82M	$10.82M
Total Long-Term Assets	$283.0K	$321.0K	$321.0K
Total Assets	$28.02M	$11.14M	$11.14M
YoY Change	125.78%	-1.38%	-1.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.16M	$29.56M	$29.56M
YoY Change	-77.45%	-52.85%	-52.87%
Accrued Expenses	$26.48M	$24.83M	$24.83M
YoY Change	0.95%	9.98%	9.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$28.92M	$29.79M	$29.79M
YoY Change	-12.63%	-13.44%	-13.44%
Total Short-Term Liabilities	$69.56M	$84.18M	$84.18M
YoY Change	-46.1%	-29.73%	-29.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$43.57M	$43.57M	$43.71M
YoY Change	17540.08%	15296.11%	15345.94%
Total Long-Term Liabilities	$43.57M	$43.57M	$43.71M
YoY Change	17540.08%	4270.21%	4284.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$69.56M	$84.18M	$84.18M
Total Long-Term Liabilities	$43.57M	$43.57M	$43.71M
Total Liabilities	$113.2M	$127.9M	$127.9M
YoY Change	-12.43%	5.88%	5.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$872.3M	-$891.5M
YoY Change	2.23%	5.92%
Common Stock	$1.220M	$1.059M
YoY Change	31.04%	15.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$85.21M	-$116.8M	-$116.8M
YoY Change
Total Liabilities & Shareholders Equity	$28.02M	$11.14M	$11.14M
YoY Change	125.78%	-1.38%	-1.38%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	$19.23M	-$17.16M	-$49.84M
YoY Change	-266.17%	-7.92%	-37.56%
Depreciation, Depletion And Amortization	$5.000K	$4.000K	$29.00K
YoY Change	-50.0%	-60.0%	-83.43%
Cash From Operating Activities	$5.440M	-$1.650M	-$10.98M
YoY Change	-221.02%	-51.64%	-56.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.667M	3.441M	11.75M
YoY Change	140.53%	154.89%	-60.74%
NET CHANGE
Cash From Operating Activities	5.440M	-1.650M	-10.98M
Cash From Investing Activities
Cash From Financing Activities	9.667M	3.441M	11.75M
Net Change In Cash	15.11M	1.791M	766.0K
YoY Change	-3273.74%	-186.86%	-84.1%
FREE CASH FLOW
Cash From Operating Activities	$5.440M	-$1.650M	-$10.98M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001175680
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.cytodyn.com/20240531#AccruedCompensationAndNonFinancingLiabilities
CY2024	dei	Entity Registrant Name EntityRegistrantName	CytoDyn Inc.
CY2024Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.cytodyn.com/20240531#AccruedCompensationAndNonFinancingLiabilities
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-05-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	000-49908
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1887078
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Main Street, Suite 660
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98660
CY2024	dei	City Area Code CityAreaCode	360
CY2024	dei	Local Phone Number LocalPhoneNumber	980-8524
CY2024	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2024	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001 per share
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	156180000
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1214900000
CY2024	dei	Auditor Firm AuditorFirmId	688
CY2024	dei	Auditor Name AuditorName	Marcum llp
CY2024	dei	Auditor Location AuditorLocation	Hartford, CT
CY2023	dei	Auditor Firm AuditorFirmId	324
CY2023	dei	Auditor Name AuditorName	Macias Gini & O’Connell LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3110000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2541000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6704000
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6507000
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	463000
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1167000
CY2024Q2	cydy	Prepaid Service Fees Current PrepaidServiceFeesCurrent	538000
CY2023Q2	cydy	Prepaid Service Fees Current PrepaidServiceFeesCurrent	590000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	10815000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	10805000
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	321000
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000
CY2024Q2	us-gaap	Assets Assets	11136000
CY2023Q2	us-gaap	Assets Assets	11292000
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	29561000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	62725000
CY2024Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	2810000
CY2023Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	6669000
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	15227000
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	10598000
CY2024Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	6791000
CY2023Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	5308000
CY2024Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	29793000
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	34417000
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	79000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	84182000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	119796000
CY2023Q2	us-gaap	Notes Payable NotesPayable	714000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	141000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283000
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43571000
CY2024Q2	us-gaap	Liabilities Liabilities	127894000
CY2023Q2	us-gaap	Liabilities Liabilities	120793000
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1750000000
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1750000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1059002000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	919053000
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1058559000
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	918610000
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1059000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	919000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	443000
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	443000
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	773714000
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	731270000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-891531000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-841690000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-116758000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-109501000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11136000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11292000
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10789000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17136000
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7240000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2632000
CY2024	us-gaap	Depreciation Depreciation	29000
CY2023	us-gaap	Depreciation Depreciation	43000
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	132000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	20633000
CY2024	us-gaap	Costs And Expenses CostsAndExpenses	18058000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	40576000
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-18058000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40576000
CY2024	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4659000
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4624000
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1076000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2126000
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	572000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	69000
CY2024	cydy	Issuance Costs For Private Placement Of Shares And Warrants Operating Activities IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities	2819000
CY2023	cydy	Issuance Costs For Private Placement Of Shares And Warrants Operating Activities IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities	9678000
CY2024	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	6680000
CY2023	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	5312000
CY2024	cydy	Finance Charge Adjustments FinanceChargeAdjustments	2367000
CY2023	cydy	Finance Charge Adjustments FinanceChargeAdjustments	8689000
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13374000
CY2024	cydy	Gain Loss On Derivatives GainLossOnDerivatives	-236000
CY2023	cydy	Gain Loss On Derivatives GainLossOnDerivatives	-8750000
CY2024	us-gaap	Interest And Debt Expense InterestAndDebtExpense	31783000
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	39248000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49841000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79824000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-49841000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	969509000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	969509000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	836528000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	836528000
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-94398000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4000000
CY2023	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	5312000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	114000
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	985000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37224000
CY2023	cydy	Offering Costs Related To Stock Issuance OfferingCostsRelatedToStockIssuance	-1760000
CY2023	cydy	Stock Issued During Period Value Warrants Exercised Net Of Offering Costs StockIssuedDuringPeriodValueWarrantsExercisedNetOfOfferingCosts	2807000
CY2023	cydy	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	439000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1331000
CY2023	cydy	Reclassification Of Warrants From Liability To Equity Classified ReclassificationOfWarrantsFromLiabilityToEquityClassified	8756000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3290000
CY2023	cydy	Adjustments To Additional Paid In Capital Finance Charges Related To Warrant Issuance For Surety Bond Backstop Agreement AdjustmentsToAdditionalPaidInCapitalFinanceChargesRelatedToWarrantIssuanceForSuretyBondBackstopAgreement	4885000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-109501000
CY2024	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5250000
CY2024	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	6680000
CY2024	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	359000
CY2024	cydy	Note Conversion NoteConversion	7150000
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	490000
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21697000
CY2024	cydy	Adjustments To Additional Paid In Capital Discount On Private Offering Modification AdjustmentsToAdditionalPaidInCapitalDiscountOnPrivateOfferingModification	137000
CY2024	cydy	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	300000
CY2024	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1483000
CY2024	cydy	Reclassification Of Warrants From Liability To Equity Classified ReclassificationOfWarrantsFromLiabilityToEquityClassified	79000
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1925000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-49841000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-116758000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-49841000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	29000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175000
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	572000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	69000
CY2024	cydy	Issuance Costs For Private Placement Of Shares And Warrants Operating Activities IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities	2819000
CY2023	cydy	Issuance Costs For Private Placement Of Shares And Warrants Operating Activities IssuanceCostsForPrivatePlacementOfSharesAndWarrantsOperatingActivities	9678000
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1076000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2126000
CY2024	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-236000
CY2023	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-8750000
CY2024	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	6680000
CY2023	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	5312000
CY2023	cydy	Finance Charges Related To Surety Bond FinanceChargesRelatedToSuretyBond	4885000
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13374000
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-6000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	20633000
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	2415000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4275000
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-893000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1902000
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10765000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3097000
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10982000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25110000
CY2023	cydy	Proceeds From Warrant Transactions Net ProceedsFromWarrantTransactionsNet	2807000
CY2024	cydy	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9137000
CY2023	cydy	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	25786000
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	300000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	439000
CY2024	cydy	Proceeds Held In Trust ProceedsHeldInTrust	300000
CY2024	cydy	Proceeds From Convertible Note And Warrant Issuances ProceedsFromConvertibleNoteAndWarrantIssuances	2011000
CY2023	cydy	Proceeds From Convertible Note And Warrant Issuances ProceedsFromConvertibleNoteAndWarrantIssuances	895000
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11748000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29927000
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	766000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4817000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9048000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4231000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9814000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9048000
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3110000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2541000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6704000
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6507000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9814000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9048000
CY2024	us-gaap	Interest Paid Net InterestPaidNet	45000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	19000
CY2024	cydy	Noncash Derivative Liability Associated With Warrants NoncashDerivativeLiabilityAssociatedWithWarrants	102000
CY2023	cydy	Noncash Derivative Liability Associated With Warrants NoncashDerivativeLiabilityAssociatedWithWarrants	8750000
CY2024	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5250000
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4000000
CY2024	cydy	Dividends On Convertible Preferred Stock Incurred But Not Yet Paid. DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.	1483000
CY2023	cydy	Dividends On Convertible Preferred Stock Incurred But Not Yet Paid. DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.	1490000
CY2023	cydy	Dividend Declared And Paid In Common Stock DividendDeclaredAndPaidInCommonStock	159000
CY2024	cydy	Warrants Issued To Placement Agent WarrantsIssuedToPlacementAgent	1783000
CY2023	cydy	Warrants Issued To Placement Agent WarrantsIssuedToPlacementAgent	7640000
CY2023	cydy	Warrants Issued For Surety Bond Backstop Agreement WarrantsIssuedForSuretyBondBackstopAgreement	4885000
CY2023Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5417000
CY2024	cydy	Note Conversion To Common Stock And Warrants NoteConversionToCommonStockAndWarrants	3302000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-49800000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79800000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-891500000
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;font-weight:normal;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP” or “GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">results of our clinical trials and/or discussions with the FDA, which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include, but are not limited to, those relating to stock-based compensation, the assumptions used to value warrants and warrant modifications. Actual results could differ from these estimates.<span style="white-space:pre-wrap;"> </span></p>
CY2024Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2900000
CY2024Q2	cydy	Restricted Cash Uninsured Amount RestrictedCashUninsuredAmount	6700000
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2300000
CY2023Q2	cydy	Restricted Cash Uninsured Amount RestrictedCashUninsuredAmount	5500000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6700000
CY2023Q2	us-gaap	Inventory Net InventoryNet	0
CY2024Q2	us-gaap	Inventory Net InventoryNet	0
CY2024	cydy	Inventory Extended Shelf Life InventoryExtendedShelfLife	P4Y
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q2	us-gaap	Inventory Net InventoryNet	0
CY2024Q2	us-gaap	Inventory Net InventoryNet	0
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	208000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	335000
CY2024Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	7000
CY2023Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	168000
CY2024Q2	cydy	Accrued Clinical Expenses AccruedClinicalExpenses	329000
CY2023Q2	cydy	Accrued Clinical Expenses AccruedClinicalExpenses	187000
CY2023Q2	cydy	Accrued Inventory Charges Current AccruedInventoryChargesCurrent	4978000
CY2024Q2	cydy	Accrued License Fees Current AccruedLicenseFeesCurrent	1799000
CY2023Q2	cydy	Accrued License Fees Current AccruedLicenseFeesCurrent	862000
CY2024Q2	cydy	Accrued Lease Payable AccruedLeasePayable	142000
CY2023Q2	cydy	Accrued Lease Payable AccruedLeasePayable	139000
CY2024Q2	cydy	Investor Proceeds Held In Escrow InvestorProceedsHeldInEscrow	300000
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25000
CY2024Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	2810000
CY2023Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	6669000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-891500000
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	30200000
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	36450000
CY2024Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	407000
CY2023Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	1319000
CY2024Q2	cydy	Long Term Debt Including Accrued Interest LongTermDebtIncludingAccruedInterest	29793000
CY2023Q2	cydy	Long Term Debt Including Accrued Interest LongTermDebtIncludingAccruedInterest	35131000
CY2024Q2	cydy	Accrued Interest Noncurrent AccruedInterestNoncurrent	15227000
CY2023Q2	cydy	Accrued Interest Noncurrent AccruedInterestNoncurrent	10598000
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	45020000
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	45729000
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	45729000
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1673000
CY2024	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1511000
CY2024	cydy	Interest Expense Accrued InterestExpenseAccrued	4659000
CY2024	cydy	Debt Conversion Fair Market Value Of Shares Exchanged For Repayment DebtConversionFairMarketValueOfSharesExchangedForRepayment	14187000
CY2024	cydy	Changes In Fair Value Of Common Stocks Of Convertible Debt ChangesInFairValueOfCommonStocksOfConvertibleDebt	-5635000
CY2024Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	45020000
CY2023Q2	cydy	Number Of Share In Unit NumberOfShareInUnit	1
CY2023Q2	cydy	Number Of Warrant In Unit NumberOfWarrantInUnit	1
CY2023Q2	cydy	Deemed Purchase Price As Percentage Of Lower Intraday Volume Weighted Average Price DeemedPurchasePriceAsPercentageOfLowerIntradayVolumeWeightedAveragePrice	0.90
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.306
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1750000000
CY2023Q4	cydy	Purchase Price Per Unit PurchasePricePerUnit	0.16
CY2024Q2	cydy	Purchase Price Per Unit PurchasePricePerUnit	0.10
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	200000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8800000
CY2023Q2	cydy	Warrant Becoming Liability WarrantBecomingLiability	16664000
CY2023	cydy	Warrant Equity Classified WarrantEquityClassified	25335000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8750000
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	79000
CY2024Q2	cydy	Warrant Becoming Liability WarrantBecomingLiability	6970000
CY2024	cydy	Warrant Equity Classified WarrantEquityClassified	7285000
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	236000
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	21500000
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
CY2023Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000
CY2023Q4	cydy	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.12
CY2023Q3	cydy	Cash And Non Cash Issuance Costs On Debt Instrument Capitalized CashAndNonCashIssuanceCostsOnDebtInstrumentCapitalized	900000
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2400000
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.306
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	52600000
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.21
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.35
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	900000
CY2024Q1	cydy	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.13
CY2024Q2	cydy	Cash And Non Cash Issuance Costs On Debt Instrument Capitalized CashAndNonCashIssuanceCostsOnDebtInstrumentCapitalized	1900000
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	200000
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.21
CY2024Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	26000000.0
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	73248
CY2022Q2	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice	0.59
CY2022	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm	P3Y2M4D
CY2022Q2	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue	352000
CY2023	cydy	Class Of Warrants Or Rights Granted ClassOfWarrantsOrRightsGranted	201771
CY2023Q2	cydy	Class Of Warrants Or Rights Granted Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedWeightedAverageExercisePrice	0.33
CY2023	cydy	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	6207
CY2023Q2	cydy	Class Of Warrants Or Rights Exercised Weighted Average Exercise Price ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice	0.63
CY2023	cydy	Class Of Warrant Or Right Exercises In Period Aggregate Intrinsic Value ClassOfWarrantOrRightExercisesInPeriodAggregateIntrinsicValue	758000
CY2023	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled	8902
CY2023Q2	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice	0.75
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	259910
CY2023Q2	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice	0.37
CY2023	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm	P4Y6M25D
CY2023Q2	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue	7276000
CY2024	cydy	Class Of Warrants Or Rights Granted ClassOfWarrantsOrRightsGranted	115582
CY2024Q2	cydy	Class Of Warrants Or Rights Granted Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedWeightedAverageExercisePrice	0.28
CY2024	cydy	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	3000
CY2024Q2	cydy	Class Of Warrants Or Rights Exercised Weighted Average Exercise Price ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice	0.10
CY2024	cydy	Class Of Warrant Or Right Exercises In Period Aggregate Intrinsic Value ClassOfWarrantOrRightExercisesInPeriodAggregateIntrinsicValue	480000
CY2024	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled	11047
CY2024Q2	cydy	Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice	0.63
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	361445
CY2024Q2	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice	0.34
CY2024	cydy	Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm	P4Y2M15D
CY2024Q2	cydy	Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue	2697000
CY2024	cydy	Class Of Warrant Or Right Outstanding And Exercisable ClassOfWarrantOrRightOutstandingAndExercisable	361445
CY2024Q2	cydy	Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Exercise Price ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageExercisePrice	0.34
CY2024	cydy	Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Remaining Contractual Term ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P4Y2M15D
CY2024Q2	cydy	Class Of Warrants Or Rights Outstanding And Exercisable Aggregate Intrinsic Value ClassOfWarrantsOrRightsOutstandingAndExercisableAggregateIntrinsicValue	2697000
CY2024	cydy	Stock Issued During Period Shares Warrants Exercised Cash StockIssuedDuringPeriodSharesWarrantsExercisedCash	3000000.0
CY2024	cydy	Stock Issued During Period Value Warrants Exercised Cash StockIssuedDuringPeriodValueWarrantsExercisedCash	300000
CY2024	cydy	Share Based Compensation Number Of Active Plans ShareBasedCompensationNumberOfActivePlans	1
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.086
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.157
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.992
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.127
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.1224
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.0706
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0396
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0383
CY2024	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2024Q2	cydy	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfSharesOutstanding	19700000
CY2023Q2	cydy	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfSharesOutstanding	12000000.0
CY2023Q2	cydy	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfSharesOutstanding	12000000.0
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	6100000
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	7800000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-49841000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79824000
CY2023	cydy	Deemed Dividend Down Round Feature Decrease In Net Income To Common Shareholder Amount DeemedDividendDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	5417000
CY2024	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1483000
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1495000
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-51324000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86736000
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	969509000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	836528000
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49800000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79800000
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	57000
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	57000
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2024	cydy	Effective Income Tax Rate Reconciliation Derivative Gain Loss Percent EffectiveIncomeTaxRateReconciliationDerivativeGainLossPercent	-0.001
CY2023	cydy	Effective Income Tax Rate Reconciliation Derivative Gain Loss Percent EffectiveIncomeTaxRateReconciliationDerivativeGainLossPercent	-0.023
CY2024	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Issuance Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtIssuanceCostsPercent	-0.071
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Issuance Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtIssuanceCostsPercent	-0.026
CY2024	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest	-0.020
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterest	-0.012
CY2024	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Induced Conversion Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnInducedConversionPercent	-0.028
CY2023	cydy	Effective Income Tax Rate Reconciliation Nondeductible Expense Loss On Induced Conversion Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnInducedConversionPercent	-0.014
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-0.006
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.072
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.012
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.008
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.137
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	100897000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96338000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2063000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2063000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2665000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	6400000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	411000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	73000
CY2024Q2	cydy	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	59000
CY2023Q2	cydy	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	89000
CY2024Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6173000
CY2023Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6173000
CY2024Q2	cydy	Deferred Tax Assets Inventory Write Off DeferredTaxAssetsInventoryWriteOff	1953000
CY2023Q2	cydy	Deferred Tax Assets Inventory Write Off DeferredTaxAssetsInventoryWriteOff	13739000
CY2024Q2	cydy	Deferred Tax Assets Contingent Liability DeferredTaxAssetsContingentLiability	9202000
CY2023Q2	cydy	Deferred Tax Assets Contingent Liability DeferredTaxAssetsContingentLiability	0
CY2024Q2	cydy	Deferred Tax Assets Warrants Issuance DeferredTaxAssetsWarrantsIssuance	3000000
CY2023Q2	cydy	Deferred Tax Assets Warrants Issuance DeferredTaxAssetsWarrantsIssuance	2317000
CY2024Q2	cydy	Section174 Rd Costs Section174RDCosts	2056000
CY2023Q2	cydy	Section174 Rd Costs Section174RDCosts	858000
CY2024Q2	cydy	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	207000
CY2023Q2	cydy	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	609000
CY2024Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	5000
CY2023Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4000
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	128691000
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	128663000
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128636000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128579000
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	55000
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	84000
CY2024Q2	cydy	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	55000
CY2023Q2	cydy	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	84000
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	55000
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	84000
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128600000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128600000
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	100000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10900000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128579000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	117638000
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	57000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10941000
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128636000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128579000
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	480500000
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	47100000
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	458800000
CY2024Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2100000
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2100000
CY2022Q3	cydy	Corporate Minimum Tax Rate CorporateMinimumTaxRate	0.15
CY2022Q3	cydy	Threshold Average Adjusted Income Amount For Corporate Minimum Tax Rate ThresholdAverageAdjustedIncomeAmountForCorporateMinimumTaxRate	1000000000
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	100000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	200000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	264000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	139000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	141000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283000
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	283000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	422000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	185000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	169000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	354000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	71000
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	283000
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001558370-24-012328-index-headers.html	Edgar Link	pending
0001558370-24-012328-index.html	Edgar Link	pending
0001558370-24-012328.txt	Edgar Link	pending
0001558370-24-012328-xbrl.zip	Edgar Link	pending
cydy-20240531.xsd	Edgar Link	pending
cydy-20240531x10k.htm	Edgar Link	pending
cydy-20240531x10k004.jpg	Edgar Link	pending
cydy-20240531xex21.htm	Edgar Link	pending
cydy-20240531xex23d1.htm	Edgar Link	pending
cydy-20240531xex23d2.htm	Edgar Link	pending
cydy-20240531xex31d1.htm	Edgar Link	pending
cydy-20240531xex31d2.htm	Edgar Link	pending
cydy-20240531xex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
cydy-20240531_cal.xml	Edgar Link	unprocessable
cydy-20240531_lab.xml	Edgar Link	unprocessable
cydy-20240531_def.xml	Edgar Link	unprocessable
cydy-20240531_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cydy-20240531x10k_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYDY
CytoDyn Inc. Stock $cydy

2024 Q3 Form 10-K Financial Statement

#000155837024012328 Filed on August 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYDY CytoDyn Inc. Stock $cydy

2024 Q3 Form 10-K Financial Statement

#000155837024012328 Filed on August 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYDY
CytoDyn Inc. Stock $cydy